You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2016MP04-12 COMORBIDITY STATUS AS A PREDICTOR OF HIGH-GRADE DISEASE IN MEN WITH PROSTATE CANCER Timothy Daskivich, Douglas Skarecky, Thomas Ahlering, and Stephen Freedland Timothy DaskivichTimothy Daskivich More articles by this author , Douglas SkareckyDouglas Skarecky More articles by this author , Thomas AhleringThomas Ahlering More articles by this author , and Stephen FreedlandStephen Freedland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1947AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES While it has long been known that advanced age is associated with higher tumor grade, it is unknown if comorbid disease burden has a similar, independent association. We sought to evaluate the impact of comorbid disease burden on risk of tumor aggressiveness as indicated by biopsy Gleason score. METHODS We conducted an observational cohort study of 1,482 men with non-metastatic prostate cancer consecutively diagnosed from 1998 to 2004 at two Southern California Veterans Affairs Medical Centers. We determined age, race, Charlson comorbidity index scores, clinical tumor stage, PSA at diagnosis, mobility status (use of walker, wheelchair, or cane), smoking history, and biopsy Gleason score from review of the electronic medical record. We categorized Charlson scores into categories of 0, 1, 2, and 3+ and Gleason scores into categories of ≤6, 7, and 8-10. We used multivariable ordinal and multinomial logistic regression to evaluate the associations between Charlson score and Gleason score after correcting for the covariates mentioned above. RESULTS Our final analytic sample comprised 1,260 men. In a multivariable ordinal logistic regression model predicting higher tumor grade, men with Charlson scores of 2 (OR 1.8, p <0.001) and 3+ (OR 1.8, p <0.001) had significantly greater odds of higher Gleason scores, compared with men with Charlson scores of 0. Other factors associated with higher tumor grade were clinical stage T2b and T2c or higher (vs. T2a or lower), higher PSA, site, and older age at diagnosis. In a multinomial logistic regression model predicting Gleason 7 vs. ≤6, only men with Charlson scores of 2 (OR 1.6, p=0.01) had greater odds of having a Gleason 7 tumor, compared with those with Charlson scores of 0. In a multinomial logistic regression model predicting Gleason 8-10 vs. ≤6, those with Charlson scores of 1 (OR 1.6, p=0.047), 2 (OR 2.8, p=0.01) and 3+ (OR 2.9, p=0.001) had higher odds of having a Gleason 8-10 tumor (Table). CONCLUSIONS Moderate-to-heavy comorbid disease burden at diagnosis is associated with higher biopsy Gleason score, independent of the impact of age. Comorbidity burden appears to be a stronger predictor of Gleason 8-10 than Gleason 7 disease. Abandoning PSA screening in sicker individuals may more often miss potentially lethal tumors. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e32-e33 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Timothy Daskivich More articles by this author Douglas Skarecky More articles by this author Thomas Ahlering More articles by this author Stephen Freedland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract